.Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AX01_Pegvisomant.Pegvisomant .Pharmacolibrary.Drugs.H_SystemicHormonalPreparationsExclSexHormonesAndInsulins.H01A_AnteriorPituitaryLobeHormonesAndAnalogues.H01AX01_Pegvisomant.Pegvisomant| name: | Pegvisomant |
| ATC code: | H01AX01 | route: | subcutaneous |
| n-compartments | 1 |
Pegvisomant is a genetically engineered growth hormone receptor antagonist used in the treatment of acromegaly, a disorder caused by excessive secretion of growth hormone, usually due to pituitary adenoma. It is a pegylated protein administered via subcutaneous injection. Pegvisomant is approved for clinical use for acromegaly in numerous countries.
Pharmacokinetic parameters reported in adult patients with acromegaly following subcutaneous administration; healthy volunteers and both sexes included in original studies.
Muto, C, et al., & Suwa, T (2011). Population pharmacokinetic and pharmacodynamic modeling of pegvisomant in asian and Western acromegaly patients. Journal of clinical pharmacology 51(12) 1628–1643. DOI:10.1177/0091270010386954 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21209237
Yang, LP, & Keating, GM (2010). Octreotide long-acting release (LAR): a review of its use in the management of acromegaly. Drugs 70(13) 1745–1769. DOI:10.2165/11204510-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20731479